Stock Ratings / Health Care / SLBT / forecast

AURA (40) CADL (38) DBVT (26) IAM (50) ⌘ Pro Terminal →

SL Science Holding Limited (SLBT) 12-Month Stock Forecast & Price Target Cone

Q: What is SLBT's 12-month stock price target?

SL Science Holding Limited (SLBT) carries a 12-month consensus base price target of $1.11 (-5.1% from $1.17), with a bull-case target of $15.23 and a bear-case floor of $0.87.

Q: Is SLBT stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates SLBT D (Sell — SELL) with an RQD Confidence score of 47/100.

$1.17 -3.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.16

SL Science Holding Limited (SLBT) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $656.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.16 (-0.79%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SLBT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY SLBT SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($18.4M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$1.51+1.3% Next Q

Q2 (-2Q)

Grade C-$1.53-24.8% Next Q

Q3 (-1Q)

Grade C-$1.15+1.7% Next Q

Current

Grade D$1.17-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SLBT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SLBT currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.89) and Max Pain ($1.23) forces dealer call-delta covering toward $15.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SLBT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SLBT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your SLBT Position Size: $10,000

Shares at $1.17: 8547.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.87

$7,436

$-2,564 (-25.6%)

12M Consensus BaseTarget $1.11

$9,487

$-513 (-5.1%)

12M Bull Case BreakoutTarget $15.23

$130,171

+$120,171 (+1201.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$14	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLBT)

✓Walkthrough of SLBT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SLBT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -87.35%⚡ TESTING RESISTANCE

2026-10-30O $1.16H $1.29L $1.16C $1.17VOL 26.6K

RES: $1.17SUP: $0.92SMA50: $1.89SMA200: $6.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SLBT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SLBT Butterfly Map → + Track SLBT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SLBT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SLBT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SLBT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLBT)

Health Care Rank #409 of 1016 ⚔️ AURA vs SLBT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SLBT vs. AURA, CADL, DBVT, IAM)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SL Science Holding Limited (SLBT) ranks #409 by composite RQD confidence (47/100, grade D) and #409 by equity capitalization ($656.1M). Within this direct 5-issuer industry benchmark cohort, SLBT leads on earnings valuation at N/A trailing P/E, while AURA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with SLBT at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SLBT ACTIVE SL Science Holding Limited	D	47/100	—	—	—	-3.31%	$656.1M	Benchmark Subject
AURA Aura Biosciences Inc.	D-	40/100	—	—	-35.0%	-1.64%	$652.8M	/aura-vs-slbt →
CADL Candel Therapeutics Inc.	D-	38/100	—	—	-35.0%	-0.23%	$661.9M	/cadl-vs-slbt →
DBVT DBV Technologies S.A.	E	26/100	—	—	-35.0%	-3.38%	$647.0M	/dbvt-vs-slbt →
IAM Iambic Therapeutics Inc.	D	50/100	—	—	—	-3.38%	$676.9M	/iam-vs-slbt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002070534

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SL Science Holding Limited (SLBT) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, SLBT closed FY2025 with $11.8K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$11.8K	—

3. SLBT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SLBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, SL Science Holding Limited (NASDAQ: SLBT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.17 (-3.31% 1D, market cap $656.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SLBT ranks #409 in composite RQD confidence.

How does SLBT compare to AURA and CADL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLBT carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AURA (Aura Biosciences Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $652.8M) and CADL (Candel Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $661.9M). Among the 5-stock peer group, SLBT leads on earnings multiple (N/A) while AURA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SLBT?

Per SLBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070534), SL Science Holding Limited generated $0 in revenue, $0 in net income, and $0 in free cash flow against $11.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SLBT trading relative to its 50-day, 200-day, and 52-week technical levels?

SLBT last traded at $1.17 (-3.31% on volume of 24,563 shares), positioning the stock -38.10% below its 50-day simple moving average ($1.89) and -80.79% below its 200-day simple moving average ($6.09). Across its 52-week range of $1.02 to $14.50, SLBT sits at the 1.1% percentile with a 14-day RSI of 29.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.02 to $1.32).

SLBT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SLBT's 12-month stock price target?

SL Science Holding Limited (SLBT) carries a 12-month consensus base price target of $1.11 (-5.1% from $1.17), with a bull-case target of $15.23 and a bear-case floor of $0.87.

Is SLBT stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates SLBT D (Sell — SELL) with an RQD Confidence score of 47/100.

Direct Sub-Reports: SLBT RQD Cockpit SLBT 12M Forecast SLBT Earnings & Move SLBT Dividends & DRIP SLBT Insiders & 13F SLBT Whale Options SLBT Profit Sankey SLBT News & Why